Management of myocardial ischemia. Is ranolazine needed? For all or some patients with myocardial ischemia?

Bibliography

• Chaitman R. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006;113:2462-72
   PubMed Web of Science ®Google Scholar
• Marzilli M, Klein WW. Efficacy and tolerability of trimetadazine in stable angina: a meta-analysis of randomized, double-blind, controlled trails. Coron Artery Dis 2003;14:171-9
   PubMed Web of Science ®Google Scholar
• Belardinelli L, Inhibition of the late sodium current as a potential cardioprotective principle effect of the late sodium current inhibitor ranolazine. Heart 2006;92:iv6-14
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA, Hod H, Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment -elevation acute coronary syndrome. Circulation 2007;116:1647-52
   PubMed Web of Science ®Google Scholar
• Lovelock JD, Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 2012;110:841-50
   PubMedGoogle Scholar
• Antzelevitch C, Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904-10
   PubMed Web of Science ®Google Scholar
• Cocco G, Dissociation in silent myocardial ischemia and time to angina: relationship with spontaneous heart rate variations. Circulation 1990;82(2):III
   Google Scholar
• Cocco G, Effect of novel metabolic modulator ranolazine on exercise tolerance and left ventricular filling dynamics in patients with angina pectoris. Eur Heart J 1992;13(A Suppl):97; A 605/1
   Google Scholar
• Cocco G, Effect of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 1992;20:131-8
   PubMed Web of Science ®Google Scholar
• Bouvy T, Improvement on exercise tolerance and left ventricular filling dynamics with the novel metabolic modulator, ranolazine. Acta Cardiol 1993;48:98-9
   Google Scholar
• Cocco G, Effect of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with alpha-blocker or diltiazem. J Cardiovasc Pharmacol 1993;20:131-8
   Google Scholar
• Rousseau MF, Is modulation of myocardial metabolism as effective as alpha-blockade in exercise-induced angina? [abstract 77643]. 43rd Ann. Sci. Session of the ACC; Atlanta, Georgia; 1993
   Google Scholar
• Rousseau MF, Ranolazine: antianginal therapy with a novel mechanism: placebo controlled comparison versus atenolol. Eur Heart J 1994;15(Suppl):P647; p95
   Google Scholar
• Rousseau MF, Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005;95:311-16
   PubMed Web of Science ®Google Scholar
• Ranexa (Ranolazine Extended Release tablets). Highlights of prescribing information. New FDA approved labeling. 2009. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Label_ApprovalHistory#labelinfo
   Google Scholar
• www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM224228.pdf
   Google Scholar
• Thadani U. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal. Expert Opin Pharmacol 2012;13(17):2555-63
   PubMed Web of Science ®Google Scholar
• Moss AJ, Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT-syndrome. J Cardiovasc Electrophysiol 2008;19:1289-93
   PubMed Web of Science ®Google Scholar
• Fragakis N, Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. AJC 2012;110:673-7
   Google Scholar
• Kumar K, Zimetbaum P. New and emerging antiarrhythmic drugs for atrial fibrillation: what may become available to the clinician in the near future. Curr Treat Options Cardiovasc Med 2009;11:373-80
   PubMedGoogle Scholar
• Murdock DK, The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "Pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J 2009;9:260-7
   PubMedGoogle Scholar
• Sossalla S, Altered Na+ currents in atrial fibrillation: effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 2010;55:2343-5
   PubMedGoogle Scholar
• Straube F, Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes. J Gen Intl Med 2011;5:531-7
   Google Scholar
• Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation 2012;125:381-9
   PubMed Web of Science ®Google Scholar
• Timmis AD, Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42-8
   PubMed Web of Science ®Google Scholar
• Morrow DA, Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 radomised controlled trial. Circulation 2009;119:2032-9
   PubMed Web of Science ®Google Scholar
• Lionetti V, Modulating fatty acid oxidation in heart failure. Cardiovasc Res 2011;90:202-9
   PubMed Web of Science ®Google Scholar
• Lovelock JD, Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 2012;110:841-50
   PubMedGoogle Scholar
• Maier LS. New treatment options for late Na+ current, arrhythmias, and diastolic dysfunction. Curr Heart Fail Rep 2012;9:183-91
   PubMedGoogle Scholar
• Jacobshagen C, Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Clin Cardiol 2011;34:426-32
   PubMed Web of Science ®Google Scholar
• Wenger NK, Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. Am J Cardiol 2007;99:11-18
   PubMedGoogle Scholar
• Mega JL. Clinical fetaures and outcomes of women with unstable ischemic heart disease. observations from metabolic efficiency with ranolazine for less Ischemia in Non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36/MERLIN-TIMI 36). Circulation 2010;121:1809-17
   PubMedGoogle Scholar
• Puja K, Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. J Am Coll Cardiol Imaging 2011;4:514-22
   Google Scholar
• Pierce DA, Ranolazine-tacrolimus interaction. Ann Pharmacother 2010;44:1844-9
   PubMed Web of Science ®Google Scholar
• http://www.drugs.com/drug-interactions/colchicine-with-ranolazine-728-0-1993-0.html
   Google Scholar
• http://arthritis.emedtv.com/colchicine/drug-interactions-with-colchicine.html
   Google Scholar
• http://reference.medscape.com/drug/colcrys-colchicine-342812#3
   Google Scholar
• Fenner KS, Drug–drug interactions mediated through P-glycoprotein: clinical relevance and in vitro–in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009;85:173-81
   PubMed Web of Science ®Google Scholar
• Belardinelli L, Hoyer K, Shyrock J. 1. (WO2010068461) Co-administration of ranolazine and cardiac glycosides. US20100130436A1; 2010
   Google Scholar
• http://www.fda.gov/ohrms/dockets/ac/03/briefing/4012B2_15_CV-Therapeutics-RANEXA.pdf
   Google Scholar
• Suckow MA, The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice. Cancer Lett 2004;209:165-9
   PubMedGoogle Scholar